Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - the EUROPE-trial

NCT02335268 is registered in ClinicalTrials.gov with Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH as lead sponsor.

NCT NCT02335268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02335268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - the EUROPE-trial
Lead sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase
Phase 2
Overall status
Completed
Start date
May 21, 2015
Completion date
July 1, 2021
Enrollment
77 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes